|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase II stud- y of carboplatin and pemetrexed for the treatment of platinum sensitive recurrent ovarian cancer 显示文摘 | Matulonis UA Horowitz NS Campos SM | 2008 | J Clin Oncol2008，26，35： | 1 |
| 2 | A phase Ⅱ trial of modified triple doublets for the treatment of advanced Müllerian malignancies显示文摘 | Matulonis UA Campos S Krasner C | 2005 | Proc Am Soc Chin Oncol2005，23，： | 1 |
| 3 | Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fal- lopian tube,or primary peritoneal carcinoma 显示文摘 | Matulonis UA Sharma S Ghamande S | 2012 | Gynecol Oncol2012，127，1： | 1 |
| 4 | Phase II study of bevacizumab in patients with platinum - resistant ovarian cancer or peritoneal serous caneer 显示文摘 | Cannistra SA Matulonis UA Penson RT | 2007 | J Clin On- eol2007，25，33： | 1 |
| 5 | Phase II study ofbevacizumab in patients with platinum-resistant ovarian cancer orperitoneal serous cancer显示文摘 | Cannistra SA Matulonis UA Penson RT | 2007 | J Clin Oncol2007，25，33： | 1 |
| 6 | Bevacizumab in patients with advanced platinum-resistant ovarian cancer显示文摘 | Cannistra SA Matulonis UA Penson R | 2006 | J Clin Oncol2006，24，18： | 1 |
| 7 | Chemotherapy hypersensitivity reactions in ovarian cancer显示文摘 | Picard M Matulonis UA Castells M | 2014 | J Natl Compr Canc Netw2014，12，3： | 1 |
| 8 | Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer 显示文摘 | Cannistra SA Matulonis UA Penson RT | 2007 | J Clin Oncol2007，25，33： | 1 |
| 9 | A phase Ⅱ trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian,primaryperitoneal serous cancer,or fallopian tube cancer显示文摘 | Berkenblit A Seiden MV Matulonis UA | | 0，，03： | 1 |
| 10 | New advances in ovarian cancer显示文摘 | Liu J Matulonis UA | 2010 | Oncology2010，24，8： | 1 |
| 11 | Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer显示文摘 | Cannistra SA Matulonis UA Penson RT | 2007 | J CLIN ONCOL2007，25，33： | 1 |
| 12 | New advances in ovarian cancer显示文摘 | Liu J Matulonis UA | 2010 | Oncology2010，24，8： | 1 |
| 13 | Phase II study ofbevacizumab in patients with platinum-resistant ovarian cancer orperitoneal serous cancer显示文摘 | Cannistra SA Matulonis UA Penson RT | 2007 | J Clin Oncol2007，25，33： | 1 |
| 14 | Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary:a focus on fertility and sexual function 显示文摘 | Campos SM Berlin S Matulonis UA | 2012 | J Psychosoc Oncol2012，30，4： | 1 |
| 15 | Hypersensitivity reactions to chemotherapy:outcomes and safety of rapid desensitization in 413 cases显示文摘 | Castells MC Tennant NM Matulonis UA | 2008 | J Allergy Clin Immunol2008，122，3： | 1 |
| 16 | Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer显示文摘 | Matulonis UA Horowitz NS Campos SM | 2008 | J Clin Oncol2008，26，： | 1 |
| 17 | Long term adjustment of early stage ovarian cancer survivors 显示文摘 | Matulonis UA Kornblith A Lee H | 2008 | Int J Gynecol Cancer2008，18，6： | 1 |
| 18 | New advances in ovarian cancer显示文摘 | Liu J Matulonis UA | 2010 | Oncology2010，24，8： | 1 |
| 19 | New advances in ovarian cancer显示文摘 | L1U J MATULONIS UA | 2010 | Oncology2010，24，8： | 1 |
| 20 | Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer 显示文摘 | MATULONIS UA BERLIN S IVY P | 2009 | J Clin Oncol2009，27，33： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员